Gyre Therapeutics, Inc. (GYRE) Stock Price & Analysis
Gyre Therapeutics, Inc. (GYRE) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $4.52 (+4.15%), as of the Nov 19, 2026 trading session; market cap $495M.
Educational signal · not a buy or sell recommendation · How to read this
Gyre Therapeutics, Inc. · GYRE · NASDAQ
Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing anti-inflammatory and anti-fibrotic drugs.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Gyre Therapeutics (GYRE)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strained balance sheet, weak growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $33M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 3 of the last 8 reports
- Altman Z 8.28 · Piotroski F 1
Holding back: balance-sheet strain, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 35 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.52 | |
| Change on the day | +4.15% | |
| 52-week range | $3.97 – $9.14 | |
| Market capitalisation | $495M | — |
| Price / earnings (trailing) | 129.11 | |
| Shares traded on the day | 268.9K |
Price & events
Other perspectives
Council score for Gyre Therapeutics (GYRE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Gyre Therapeutics (GYRE), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Gyre Therapeutics, Inc. (GYRE) is listed on NASDAQ. It employs 625 people and is led by Ying Luo. In Q3 FY2026 it reported revenue of $33M and net income of -$4M. The market values it at $495M.
What do the latest results show for Gyre Therapeutics (GYRE)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $33M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $33M | -$4M | -$0.04 (diluted) |
| Q2 FY2026 | $29M | -$11M | -$0.12 (diluted) |
| Q1 FY2026 | $23M | -$9M | -$0.10 (diluted) |
| Q4 FY2025 | $37M | -$2M | -$0.02 (diluted) |
What are the financial strengths and risks for Gyre Therapeutics (GYRE)?
Short answer · as of
What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z 8.28 · Piotroski F 1. Trailing ratios: ROE -22.4% · ROA -12.4% · current ratio 4.32 · earnings yield -5.5% · free-cash-flow yield -5.5%.
Data-derived red flags
- Negative return on equity (-22.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How does Gyre Therapeutics compare with its peers?
Short answer
Gyre Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Gyre Therapeutics (GYRE) — this page | $4.52 | $495M | 34 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GYRE in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GYRE in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Gyre Therapeutics (GYRE)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for GYRE?
GYRE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is GYRE a good stock to buy?
Stock Expert AI does not rate GYRE buy, sell or hold. Gyre Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GYRE stock price today?
The last price recorded for Gyre Therapeutics, Inc. (GYRE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for GYRE?
Gyre Therapeutics, Inc. (GYRE) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Analysts target $17.00 (+276%). ETUARY (Pirfenidone) is approved for idiopathic pulmonary fibrosis, providing a stable revenue stream. Not financial advice.
How frequently does GYRE data refresh on this page?
GYRE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GYRE's recent stock price performance?
Gyre Therapeutics, Inc. (GYRE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (ETUARY) for idiopathic pulmonary fibrosis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GYRE overvalued or undervalued right now?
The trailing P/E of Gyre Therapeutics, Inc. (GYRE) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of GYRE?
Fractional-share availability for Gyre Therapeutics, Inc. (GYRE) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track GYRE's earnings and financial reports?
Gyre Therapeutics, Inc. (GYRE) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for GYRE earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com